Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Study Number: 

PH 269015

Phase: 
Early Phase
Trial categories: 
Non-Small Cell Lung Cancer (NSCLC)
Lung
Skin Cancer
Melanoma
Immunotherapy
Early Phase Clinical Trial
Antibody therapy
Checkpoint blockade
Principal Investigator: